The science driving personalized medicine continues to push innovation toward better patient care, but successful innovation requires technology development incentives and appropriate policies governing regulatory oversight of novel diagnostic tests and testing platforms. This panel will provide insight into the evolving status of regulatory oversight of various types of advanced diagnostics, discuss current and evolving policy at FDA and CMS, and explore the potential impact that these developments will have on medical research, product development, and market access.

Ability Level: Intermediate

Session ID: 21134